MACROGENICS INC(MGNX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

MACROGENICS INC (MGNX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MGNX at 39.6/100 on a 32-signal composite quality model, placing it at rank #2,142 of 2,960 stocks — the bottom half of the AI-ranked universe. MGNX scores in the top quartile across revenue growth (97.4), institutional flow (86.4). Areas of concern include earnings quality (1.3) and free cash flow (10.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MACROGENICS INC reports quarterly revenue of $32.8M, net income of $19.5M, an operating margin of -42.2%. Top institutional holders of MGNX by reported 13-F value include ARMISTICE CAPITAL, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MGNX trades on the Nasdaq exchange and files with the SEC under CIK 1125345. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MGNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MACROGENICS INC directly from SEC EDGAR.